VectivBio has its IPO on Nasdaq

Niederer Kraft Frey advised the banking syndicate, led by BofA Securities, SVB Leerink and Credit Suisse, in connection with the initial public offering of VectivBio Holding AG and the listing of its shares on Nasdaq. Through its IPO, which priced on 8 April 2021 at USD 17 per share, VectivBio raised gross proceeds of USD 146.6 million (including greenshoe). At market close on the first day of trading, VectivBio had a market capitalisation of USD 824 million.

VectivBio is a clinical stage biopharmaceutical company focused on the discovery, development and commercialisation of innovative treatments for severe rare conditions for which there is a significant unmet medical need.

The NKF team was led by Capital Markets partners Thomas Brönnimann and Philippe Weber, working with senior associate Deirdre Ni Annrachain (Capital Markets), partner Markus Kronauer and associate Vanessa Witschi (both Tax).

Practice Areas